[The endocrine profile in prostatic cancer: therapeutic implications].
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000315:Adrenalectomy; D000616:Aminoglutethimide / Q000627:therapeutic use; D000726:Androgen Antagonists / Q000627:therapeutic use*; D000728:Androgens / Q000502:physiology*; D002369:Castration; D003534:Cyproterone / Q000627:therapeutic use; D004967:Estrogens / Q000627:therapeutic use; D005485:Flutamide / Q000627:therapeutic use; D006728:Hormones / Q000502:physiology*; D006801:Humans; D007016:Hypophysectomy; D007986:Luteinizing Hormone / Q000378:metabolism; D008297:Male; D009376:Neoplasms, Hormone-Dependent / Q000503:physiopathology*; D011372:Progestins / Q000627:therapeutic use; D011388:Prolactin / Q000037:antagonists & inhibitors; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000209:etiology / Q000378:metabolism* / Q000628:therapy; D013148:Spironolactone / Q000627:therapeutic use
D000305:Adrenal Cortex Hormones; D000726:Androgen Antagonists; D000728:Androgens; D004967:Estrogens; D006728:Hormones; D011372:Progestins; D000616:Aminoglutethimide; D013148:Spironolactone; D005485:Flutamide; D011388:Prolactin; D007986:Luteinizing Hormone; D003534:Cyproterone
Perfil endocrino del carcinoma prostático: implicaciones terapéuticas.